Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Pediatr Infect Dis J. 2013 Aug;32(8):851–855. doi: 10.1097/INF.0b013e31828c3738

Figure 1. Probability of achieving Viral suppression (<400 copies/ml) by 12 months stratifying by whether stavudine/lamivudine (d4T/3TC) or abacavir/lamivudine (ABC/3TC) was used among children initiating ritonavir-boosted lopinavir (LPV/r)-based therapy (Panel A) or efavirenz (EFV)-based therapy (Panel B) and Probability of maintaining suppression (<1000 copies/ml) stratifying by whether d4T/3TC or ABC/3TC was used among children initiating LPV/r-based therapy (Panel C) or EFV-based therapy (Panel D).

Figure 1

The shaded areas represent 95% confidence limits. Abbreviation: Viral Load (VL)